# Rule 5 — R5-M6B Medicine Evidence Audit: A2 (Angioitico-2)

## 1. Document control

| Field | Value |
|-------|--------|
| **Owner** | Dr. Ghanshyam Bakalwar |
| **Phase** | R5-M6B |
| **Audit sequence** | 2 of 38 |
| **Medicine code** | A2 |
| **Classification** | DOCUMENTATION_ONLY_MEDICINE_AUDIT |
| **Audit record version** | 1.0 |
| **Audit date** | 2026-08-08 |
| **Repository base (EHAS2)** | `de1d502cdc89d17eba2869e715720c1b23020874` |
| **Framework** | [rule-05-medicine-evidence-audit-framework-R5-M6B.md](./rule-05-medicine-evidence-audit-framework-R5-M6B.md) |
| **Index** | [rule-05-medicine-evidence-audit-index-R5-M6B.md](./rule-05-medicine-evidence-audit-index-R5-M6B.md) |

---

## 2. Repository / base / registry identity

| Item | Value |
|------|--------|
| **Canonical repository** | `bakalwar/EH_AROGYA_SUTRA_2` |
| **Registry version** | `ehas2-medicine-registry-v2` |
| **Medicine count** | 38 |
| **C11** | Excluded (`registry.v2.manifest.json` → `excludedCodes: ["C11"]`) |
| **Owner decision CQ-001A** | Canonical 38-code identity only — not clinical approval |
| **Registry v2 blob (@ base)** | `packages/medicine-registry/src/medicines.v2.json` · git blob `5bba8d6fe05effc775e88ddfba93c1e572f069cb` |
| **Manifest (@ base)** | `packages/medicine-registry/src/registry.v2.manifest.json` · `artifactSha256`: `1C29F194B4B8EF6B45DBE75FE82EA7F660A51F48952BB7050B9A0BD86990B814` |

---

## 3. Audit scope and non-authorization banner

This record is a **documentation-only** source and governance audit for **A2**. It:

- Inventories and compares sources; records conflicts and owner decisions **as documentation**.
- Does **not** clinically validate A2, authorize potency/dosage, activate evidence, connect orchestration, or approve Rule 6 medicine relationships.
- Does **not** endorse cure, guarantee, default medicine, or keyword-priority selection authority.
- Treats owner-provided text **existence** as provenance fact — **not** as clinical truth.

**Posture flags (final):**

| Flag | Value |
|------|--------|
| `clinicallyValidated` | `false` |
| `rule5SafetyCoverageComplete` | `false` |
| `potencyAuthorized` | `false` |
| `dosageAuthorized` | `false` |
| `evidenceActivated` | `false` |
| `runtimeAuthorized` | `false` |

---

## 4. A2 canonical identity

| Field | Registry v2 | Owner-primary block | Notes |
|-------|-------------|---------------------|--------|
| **Code** | `A2` | `A2` | Matches CQ-001A set |
| **Display name** | `Angioitico-2` | `ANGIOTICOS-2 (A2)` | Spelling variant only |
| **Group** | `Angioitico` | A-Group (Angioticos) | Consistent |
| **Medicine number** | Not in v2 row | `22` | Owner-only metadata |
| **C11 remap** | **No** | **No** | C11 not used for A2 |

**No-remap confirmation:** A2 remains code `A2`; no substitution from excluded C11.

---

## 5. Sources and provenance table

| Source ID | Classification (framework §3) | Reference | Tracked in EHAS2 Git | Blob / status | Provenance | License |
|-----------|------------------------------|-----------|----------------------|---------------|------------|---------|
| **SRC-A2-OWNER** | `OWNER_PROVIDED_SOURCE_CANDIDATE` | Cursor transcript session `019c5012-fbb1-4582-a4af-af8484d1bc5f` (user message ~line 1441); normalized corpus `MED=A2` | Corpus: **NOT_GIT_TRACKED** in EHAS2 | See **§5.1 corpus integrity** · primary narrative lines **931–967** | **Located, not verified** | **Not verified** |
| **SRC-A2-MM1E** | `NORMALIZED_OWNER_TEXT_COPY` | Legacy project `docs/phase-s5-mm1e/_doctor_medicine_corpus.txt` (`MED=A2` … before `MED=A3`) | **WORKTREE_ONLY** (legacy repo) | Same byte anchor as §5.1 A2-block scope | Derived copy of owner block | N/A |
| **SRC-A2-REG-V2** | `CURRENT_EHAS2_REGISTRY_V2` | `packages/medicine-registry/src/medicines.v2.json` (A2 object) | **Tracked @ de1d502** | Blob `5bba8d6…` (whole file) | Identity/metadata structure | N/A |
| **SRC-A2-ENGINE** | `LEGACY_NORMALIZED_ENGINE_COPY` | Legacy `eh-api/data/engine_medicines_38.py` (`MEDICINES_38` A2 dict) | Legacy repo tracked lineage | Comparison only | Developer normalization | N/A |
| **SRC-A2-MM2** | `NORMALIZED_OWNER_TEXT_COPY` | Legacy `docs/phase-s5-mm2/S5MM2_MASTER_MATERIA_MEDICA.json` (A2 entry) | **WORKTREE_ONLY** | MM2 `temperament_affinity`: **not populated** (primary block located) | Parsed from owner corpus | N/A |
| **SRC-A2-MM3** | `HISTORICAL_OR_CONFLICTING_LEGACY_SOURCE` | Legacy `docs/phase-s5-mm3/S5_MM3_MASTER_MATERIA_MEDICA.json` (`A2` row) | **WORKTREE_ONLY** | BOOK + doctor segments; OCR-derived | **UNVERIFIED_BOOK_DERIVED_TEXT** | **Not verified** |
| **SRC-A2-BOOK** | `HISTORICAL_OR_CONFLICTING_LEGACY_SOURCE` | BOOK chain via MM3 `evidence: BOOK` / `EH_BOOK_MASTER_HINDI.txt` segments | **WORKTREE_ONLY** | Extended disease lists, dilution OCR fragments | **UNVERIFIED_BOOK_DERIVED_TEXT** | **Not verified** |

Untracked legacy sources are **not** merged Git authority for EHAS2.

### 5.1 Corpus integrity (read-only recompute)

Legacy normalized corpus (untracked working tree). **No legacy files edited.** Methods: `git hash-object` (Git blob SHA-1); `SHA-256` over **on-disk bytes** (Node `crypto.createHash('sha256')`).

| Scope | Relative path / boundary | Byte length | Line endings (on disk) | Git tracking | Git blob SHA-1 | SHA-256 (raw bytes) |
|-------|--------------------------|------------:|------------------------|--------------|----------------|---------------------|
| **Whole file** | `docs/phase-s5-mm1e/_doctor_medicine_corpus.txt` | 424,565 | **CRLF** throughout | **NOT_GIT_TRACKED** (legacy repo) | `f4bc49f70d8482824bc06f8d21dae673cba8ee9e` (`--no-filters`; default filters on this host match for whole-file read) | `9ecd7e87bf0ed5865df70c1bd49adcd093f557d3cdb5a0f56c9a0e85bc82e4c1` |
| **A2 normalized block** | From first `MED=A2` through byte before `MED=A3` (includes section headers + `<user_query>` … `</user_query>`) | 6,432 | **CRLF** (substring of whole file) | **NOT_GIT_TRACKED** | `f1c5835be013741b9bda7360bfbf61f4766e4489` | `37f80251f2ec82e68136f0439ad82ed8966cda7ba3a6cf685aa946cbc8ac621d` |

**Statement inventory check:** Primary owner narrative (lines 931–967 / `<user_query>` body) **unchanged** vs pre-audit read-only inventory; audit **continues** (no content drift blocker).

---

## 6. Source lineage / independence

| Relationship | Assessment |
|--------------|------------|
| Owner → MM1E corpus | **Duplicate / normalized copy** |
| Owner → MM2 | **Derived** from owner block; structured metadata, not new primary temperament labels |
| Engine → Registry v2 A2 row | **Near-identical English fields** (legacy normalization copied into v2) |
| MM3 BOOK → Owner | **Independent BOOK chain** with OCR noise; **must not merge** with owner-primary (CQ-003) |
| Expert tip (S1+A2) → `temperament_affinity` | **Conflation** in engine/registry — combo folded into temperament field |
| A1 vs A2 | **Distinct owner blocks** — arterial (A1) vs venous (A2); no code remap |

**First appearance of `Lymphatic`, `Bilious`, S1+A2 on A2:** legacy engine + registry v2; **not** in owner-primary block. Introducing commit fine-grained bisect: **UNKNOWN** (not performed in this audit).

---

## 7. Owner-primary statement inventory

**Label:** `EXHAUSTIVE_PRIMARY_BLOCK_STATEMENT_INVENTORY` — **38** distinct statement rows (**A2-CLM-001** through **A2-CLM-038**) covering the verified primary block (corpus lines 931–967). Rows are **inventory references**, not atomic clinical validations.

| ID | Category | Short paraphrase (owner-primary) |
|----|----------|----------------------------------|
| A2-CLM-001 | Identity | A2 is venous protector / blood purifier in EH materia. |
| A2-CLM-002 | Identity | Master medicine for impure venous blood and **right-side** circulation. |
| A2-CLM-003 | Identity | Medicine number 22: ANGIOTICOS-2 (A2). |
| A2-CLM-004 | Identity | Aliases: Venous Master; Blood Purifier. |
| A2-CLM-005 | Philosophy | Main role: control veins and venous blood return from organs to heart. |
| A2-CLM-006 | Philosophy | Works on vessels carrying impure blood (CO₂-rich) vs A1 on arteries. |
| A2-CLM-007 | Philosophy | Described as among EH’s strongest blood-purifier medicines. |
| A2-CLM-008 | Affinity | Veins — walls and internal valves. |
| A2-CLM-009 | Affinity | Portal circulation between liver and digestive organs. |
| A2-CLM-010 | Affinity | Right heart — receives impure blood. |
| A2-CLM-011 | Affinity | Skin and glands — disorders from blood impurity. |
| A2-CLM-012 | Indication | Varicose veins — swelling, bluish color, pain. |
| A2-CLM-013 | Indication | Varicocele — testicular vein congestion. |
| A2-CLM-014 | Indication | Piles/hemorrhoids — venous swelling in rectum. |
| A2-CLM-015 | Indication | Phlebitis — internal vein inflammation. |
| A2-CLM-016 | Indication | Skin eruptions, acne from impure blood. |
| A2-CLM-017 | Indication | Eczema and itching with blood toxins. |
| A2-CLM-018 | Indication | Chronic venous ulcers from poor circulation. |
| A2-CLM-019 | Indication | Portal congestion / liver blood pressure. |
| A2-CLM-020 | Indication | Fatty liver and organ heaviness from blood stasis. |
| A2-CLM-021 | Indication | Venous hemorrhage — dark/slow bleeding. |
| A2-CLM-022 | Indication | Menorrhagia from uterine venous pressure. |
| A2-CLM-023 | Potency narrative | Low dilution D1–D3 **Positive** — slow flow, vein tone, open glands. |
| A2-CLM-024 | Potency narrative | **D5 NEUTRAL** within low-band narrative. |
| A2-CLM-025 | Potency narrative | High dilution **D10–D500 Negative** — venous burning, bleeding piles, acute detox. |
| A2-CLM-026 | Tags | Keyword tag: Venous-Master. |
| A2-CLM-027 | Tags | Keyword tag: Varicose-Veins-Remedy. |
| A2-CLM-028 | Tags | Keyword tag: Blood-Cleanser. |
| A2-CLM-029 | Tags | Keyword tag: Hemorrhoids-Venous-Support. |
| A2-CLM-030 | Tags | Keyword tag: Portal-Congestion-Cure. |
| A2-CLM-031 | Tags | Keyword tag: Varicocele-Treatment. |
| A2-CLM-032 | Tags | Keyword tag: Venous-Ulcer-Healer. |
| A2-CLM-033 | Expert tip | If DB keywords include varicose/piles/blood purifier/venous congestion/varicocele → prioritize A2. |
| A2-CLM-034 | Expert tip | S1+A2 combination described as famous EH blood tonic for blood purification. |
| A2-CLM-035 | Instruction | Save block as A2 master data for database (authoring instruction). |
| A2-CLM-036 | Group context | Contrasts with A1 arterial focus within Angioticos series. |
| A2-CLM-037 | Mapping | Disease mapping sections A–D for 116k DB authoring (venous, skin, portal, hemorrhage). |
| A2-CLM-038 | Scope | Right-side body emphasis in introductory identity. |

**Temperament:** No owner-primary row for Lymphatic, Bilious, or `temperament_affinity`.

---

## 8. Registry / legacy comparison

| Field | Owner-primary | Registry v2 / legacy engine | Conflict |
|-------|---------------|------------------------------|----------|
| `polarity` (medicine-level) | Low band Positive; high band Negative narrative | `POSITIVE` (single field) | **Wording model mismatch** |
| `potency_logic` | D5 **NEUTRAL**; high **D10–D500** | D1–D5 POSITIVE; high **D10–D200** | **Yes** — band ceiling + D5 polarity |
| `temperament_affinity` | **Absent** | Lymphatic (blood toxins), Bilious (portal heat); S1+A2 expert clause | **Yes** — derived addition |
| English normalization | Hindi/Hinglish primary | Condensed English strings | Expected normalization; not clinical upgrade |
| Expert tip | Separate prose | Embedded in `temperament_affinity` and `description` | **Conflation** |
| Right-side / venous focus | Explicit in owner identity | Present in English `target_organ` | Aligned at descriptive level |

Registry v2 A2 row matches legacy `engine_medicines_38.py` on compared fields (string parity on sampled fields).

---

## 9. Potency scope separation (CQ-001 / CQ-002)

| Track | Authority | A2 fact |
|-------|-----------|---------|
| **Rule 4 formula-selection potency** | Merged Rule 4 governance (automatic scale D1–D60; D100/D200/D500 auto **prohibited**) | **Unchanged** by this audit |
| **A2 medicine-specific potency narrative** | Owner-primary descriptive text only | D5 **NEUTRAL**; D10–D500 **Negative** band in owner text |
| **Registry/legacy potency_logic** | Descriptive conflict reference | D5 **Positive** grouping; **D10–D200** ceiling |

**Owner decisions recorded (documentation):**

- **`R5-M6B-A2-CQ-001 = A`** — Separate tracks; Rule 4 D5 Positive group unchanged; owner D5 Neutral preserved as source text; registry/legacy D5 Positive conflict preserved; no executable potency authority.
- **`R5-M6B-A2-CQ-002 = A`** — `descriptive_source_text_only`; owner `D10–D500` preserved; Rule 4 automatic selection limits unchanged; registry `D10–D200` conflict preserved; MM3 BOOK high-potency fragments quarantined; no potency/dosage authorization.

---

## 10. BOOK quarantine (CQ-003)

MM3/BOOK-derived A2 material (extended disease OCR lists, dilution fragments, `high_potency`: `D10; D30`, route/use OCR) is classified:

- **`UNVERIFIED_BOOK_DERIVED_TEXT`**
- **`inventory_reference_allowed`**
- **`zero_clinical_authority`**
- **`no_merge_with_owner_primary`**

Bibliographic identity, license, page binding, and OCR integrity for BOOK sources: **NOT_VERIFIED**. BOOK evidence does **not** count toward Rule 5 safety completion.

**Owner decision:** **`R5-M6B-A2-CQ-003 = A`** (scopes above).

---

## 11. Temperament-affinity quarantine (CQ-004)

| Concept | Owner-primary | Registry/legacy |
|---------|---------------|-----------------|
| Lymphatic (blood toxins) | **Silent** | Present in `temperament_affinity` |
| Bilious (portal heat) | **Silent** | Present |
| S1 + A2 pairing | Expert tip (separate) | Appended inside `temperament_affinity` |
| Keyword priority | Expert tip (separate) | Not verbatim in registry field |

MM2 A2: primary doctor block **located**; no owner-verbatim temperament column. MM3 A2: `temperament`: **`UNKNOWN`**.

**Owner decision:** **`R5-M6B-A2-CQ-004 = A`** — `DERIVED_UNVERIFIED_AFFINITY_METADATA`; expert tip and S1+A2 pairing remain **separate inventory concepts**; **zero** Rule 6 medicine-level relationship authority; no default/priority/candidate effect from registry presence.

---

## 12. Rule 5 fourteen-domain safety gap register

Domains use framework §5.7 vocabulary only. **BOOK-only** rows marked quarantined — **zero safety-completion credit**.

| # | Domain | Owner-primary | Registry/legacy | MM3 BOOK-derived | Status |
|---|--------|---------------|---------------|------------------|--------|
| 1 | Contraindications | **SOURCE_NOT_FOUND** | **SOURCE_NOT_FOUND** | `contraindications`: UNKNOWN / OCR fragments | **OWNER_REVIEW_REQUIRED** · BOOK = UNVERIFIED |
| 2 | Allergy / hypersensitivity | **SOURCE_NOT_FOUND** | **SOURCE_NOT_FOUND** | **SOURCE_NOT_FOUND** | **SOURCE_NOT_FOUND** |
| 3 | Adverse effects | **SOURCE_NOT_FOUND** | **SOURCE_NOT_FOUND** | Caution/route OCR text | **OWNER_REVIEW_REQUIRED** · BOOK quarantined |
| 4 | Medicine–medicine interactions | **SOURCE_NOT_FOUND** | **SOURCE_NOT_FOUND** | Combination / internal+external OCR | **OWNER_REVIEW_REQUIRED** · BOOK quarantined |
| 5 | Medicine–condition interactions | **SOURCE_NOT_FOUND** | **SOURCE_NOT_FOUND** | Partial BOOK lists | **OWNER_REVIEW_REQUIRED** |
| 6 | Route incompatibility | **SOURCE_NOT_FOUND** | **SOURCE_NOT_FOUND** | Internal/external use OCR | **OWNER_REVIEW_REQUIRED** · BOOK quarantined |
| 7 | Overdose / exposure | **SOURCE_NOT_FOUND** | **SOURCE_NOT_FOUND** | **SOURCE_NOT_FOUND** | **SOURCE_NOT_FOUND** |
| 8 | Duration / cumulative use | **SOURCE_NOT_FOUND** | **SOURCE_NOT_FOUND** | **SOURCE_NOT_FOUND** | **SOURCE_NOT_FOUND** |
| 9 | Monitoring targets | **SOURCE_NOT_FOUND** | **SOURCE_NOT_FOUND** | **SOURCE_NOT_FOUND** | **SOURCE_NOT_FOUND** |
| 10 | Pause criteria | **SOURCE_NOT_FOUND** | **SOURCE_NOT_FOUND** | **SOURCE_NOT_FOUND** | **SOURCE_NOT_FOUND** |
| 11 | Stop criteria | **SOURCE_NOT_FOUND** | **SOURCE_NOT_FOUND** | **SOURCE_NOT_FOUND** | **SOURCE_NOT_FOUND** |
| 12 | Emergency / red-flag criteria | **SOURCE_NOT_FOUND** | **SOURCE_NOT_FOUND** | **SOURCE_NOT_FOUND** | **SOURCE_NOT_FOUND** |
| 13 | Follow-up timing | **SOURCE_NOT_FOUND** | **SOURCE_NOT_FOUND** | **SOURCE_NOT_FOUND** | **SOURCE_NOT_FOUND** |
| 14 | Special populations | **SOURCE_NOT_FOUND** | **SOURCE_NOT_FOUND** | BOOK disease lists mention pregnancy-related terms (OCR) | **OWNER_REVIEW_REQUIRED** · BOOK quarantined |

**`OWNER_REVIEW_REQUIRED` meaning (this audit):** required **action / governance status** only — **not** Rule 5 safety completion. It does **not** verify BOOK OCR text, does **not** close safety gaps, and does **not** assign `OWNER_APPROVED`, `VALIDATED`, or `ACTIVE`.

**Rule 5 implementation posture (EHAS2):** `NOT_IMPLEMENTED` (framework/index). No domain reaches `OWNER_APPROVED`.

---

## 13. Conflict register

| Conflict ID | Summary | Resolution posture |
|-------------|---------|-------------------|
| **CF-A2-001** | Owner D5 NEUTRAL vs registry/legacy D5 in Positive low band | **Preserved** — CQ-001 = A |
| **CF-A2-002** | Owner D10–D500 vs registry D10–D200 | **Preserved** — CQ-002 = A |
| **CF-A2-003** | MM3 BOOK `D10; D30` vs owner/registry bands | **Quarantine** — CQ-002 = A, CQ-003 = A |
| **CF-A2-004** | Registry `temperament_affinity` vs owner silence | **Preserved** — CQ-004 = A |
| **CF-A2-005** | MM3 BOOK safety/disease OCR vs owner-primary absence | **Quarantine** — CQ-003 = A |
| **CF-A2-006** | Expert tip keyword priority vs no-default medicine governance | **Closed** — `REJECTED_BY_EXISTING_GOVERNANCE`; historical source narrative preserved; no selector/default/candidate authority |
| **CF-A2-007** | Medicine-level `polarity: POSITIVE` vs bidirectional potency narrative | **Preserved** — descriptive conflict |

No silent merge applied in this audit record.

---

## 14. Owner decisions — four full IDs

| Decision ID | Option | Scope (summary) |
|-------------|--------|-----------------|
| **R5-M6B-A2-CQ-001** | **A** | Rule 4 selection vs A2 potency narrative **separate tracks**; Rule 4 D5 Positive group unchanged; owner D5 Neutral as source text; registry D5 Positive conflict preserved; **no executable potency authority** |
| **R5-M6B-A2-CQ-002** | **A** | `descriptive_source_text_only`; owner D10–D500 preserved; Rule 4 auto scale unchanged; D100/D200/D500 auto selection prohibited; registry D10–D200 conflict preserved; MM3 quarantined; **no potency/dosage authorization** |
| **R5-M6B-A2-CQ-003** | **A** | `UNVERIFIED_BOOK_DERIVED_TEXT`; inventory reference allowed; zero clinical authority; no merge with owner-primary; BOOK does not complete Rule 5 safety |
| **R5-M6B-A2-CQ-004** | **A** | `DERIVED_UNVERIFIED_AFFINITY_METADATA`; owner silent on Lymphatic/Bilious; expert tip / S1+A2 separate; **zero** Rule 6 medicine relationship authority |

These decisions are **documentation of owner authorization** for audit posture — **not** clinical validation or implementation approval.

---

## 15. Rule 1 / 4 / 5 / 6 boundaries

### Rule 1 (patient temperament)

- Frozen temperament logic separate from disease ranking and final medicine selection (`rule-01-temperament-engine.md`).
- Q3G-TIE / **`UNRESOLVED_TIE`** — no default medicine from equal tie (`rule-01-q3-precontract-owner-decisions.md`).
- Registry/materia narrative **non-authoritative** as patient evidence where governance lists it.
- A2 registry `temperament_affinity` **must not** be read as Rule 1 patient-temperament evidence.

### Rule 4 (potency selection)

- Automatic dilution selection: merged frozen scale **D1–D60**; **D100/D200/D500** automatic selection **prohibited**.
- A2 owner potency bands remain **descriptive materia-medica text** unless separately authorized.

### Rule 5 (dosage / safety)

- **NOT_IMPLEMENTED**; this audit **does not** complete safety domains.

### Rule 6 (medicine relationships)

| Layer | Posture @ audit base `de1d502` |
|-------|--------------------------------|
| **Scaffold / code (`nineRules.ts`)** | Rule 6 `phase5bStatus`: **`READY_FOR_VALIDATION`**; `ORCHESTRATION_STATUS`: **`NOT_CONNECTED`** — **scaffold readiness only, not medicine-level approval** |
| **R5-M6B framework/index wording** | Rule 6 documented as **`NOT_STARTED`** for medicine-evidence program |
| **Audit note** | **`READY_FOR_VALIDATION` ≠ A2 relationship approved** — interface/scaffold readiness only |
| **A2 medicine-level relationship (incl. S1+A2)** | **`NOT_APPROVED` / `ZERO_AUTHORITY`** — registry presence creates **no** eligibility, priority, or default |
| **Clinical activation** | **None** |

---

## 16. Final classification

| Dimension | Classification |
|-----------|----------------|
| **Canonical identity** | **VERIFIED** (CQ-001A / registry v2) |
| **Owner-primary materia block** | **LOCATED** — `OWNER_PROVIDED_SOURCE_CANDIDATE` |
| **Clinical validation** | **NOT_VALIDATED** |
| **Registry descriptive metadata** | **LEGACY_NORMALIZED_ENGINE_COPY** alignment |
| **Temperament affinity** | **DERIVED_UNVERIFIED_AFFINITY_METADATA** |
| **BOOK/MM3 adjunct** | **UNVERIFIED_BOOK_DERIVED_TEXT** |
| **Rule 5 safety** | **INCOMPLETE / BLOCKED** |
| **Evidence lifecycle** | **NONE activated** |

**Verdict code:** `A2_DOCUMENTATION_AUDIT_COMPLETE_CLINICAL_AND_SAFETY_BLOCKED`

---

## 17. Remaining blockers

1. Rule 5 fourteen-domain completion requires **complete source provenance**, applicable **owner governance review**, and **independent clinical validation** where required; **owner acknowledgment/approval alone does not** make missing safety evidence verified, sufficient, or complete.
2. BOOK bibliographic verification gate before any BOOK text adoption.
3. Explicit owner decisions if registry descriptive fields should ever supersede or reconcile with owner-primary (beyond documented CQ-001–004 preservation posture).
4. Rule 6 medicine-level relationship authorization (including S1+A2) — **separate future owner phase**; not implied by this audit.
5. Provenance/license verification for owner transcript and normalized corpus in EHAS2 tracked artifacts.
6. **Closed boundary (not an open blocker):** keyword-priority expert tip is **rejected** for current EHAS2 selector use (`REJECTED_BY_EXISTING_GOVERNANCE`); future reconsideration requires a **new explicit owner supersession decision**. Historical owner text remains in §7 inventory only.

**Next eligible medicine in canonical sequence:** **A3 — NOT_STARTED; no audit target authorization in this PR.** No A3 audit file in this task.

---

## 18. Mandatory footer (audit record)

| Item | Value |
|------|--------|
| Medicine audited (documentation) | A2 |
| Clinically validated | NO |
| Rule 5 safety complete | NO |
| Evidence activated | NONE |
| Potency authorized | NO |
| Dosage authorized | NO |
| Rule 6 A2 relationship approved | NO |
| Registry JSON changed | NO |
| C11 implicated | NO |
| Runtime changed | NO |

**Authority tag:** `DOCUMENTATION_ONLY_MEDICINE_AUDIT` · **Owner decisions recorded as documentation · not implementation approval**
